The companies said the study in patients with HER2-expressing advanced breast and bladder cancer is expected to begin enrollment in the first quarter of 2018.
This article was provided by Reuters.
This copy is for your personal, non-commercial use only. Reproductions and distribution of this news story are strictly prohibited.
August 28, 2017
The companies said the study in patients with HER2-expressing advanced breast and bladder cancer is expected to begin enrollment in the first quarter of 2018.
This article was provided by Reuters.
This copy is for your personal, non-commercial use only. Reproductions and distribution of this news story are strictly prohibited.